{"organizations": [], "uuid": "9df7550fe2296751b261ef43d331523b0e10f91c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-alder-biopharmaceuticals-enters-in/brief-alder-biopharmaceuticals-enters-into-european-patent-settlement-global-license-agreement-with-teva-idUSFWN1P30L8", "country": "US", "domain_rank": 408, "title": "BRIEF-Alder Biopharmaceuticals Enters Into European Patent Settlement, Global License Agreement With Teva", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.824, "site_type": "news", "published": "2018-01-08T21:33:00.000+02:00", "replies_count": 0, "uuid": "9df7550fe2296751b261ef43d331523b0e10f91c"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-alder-biopharmaceuticals-enters-in/brief-alder-biopharmaceuticals-enters-into-european-patent-settlement-global-license-agreement-with-teva-idUSFWN1P30L8", "ord_in_thread": 0, "title": "BRIEF-Alder Biopharmaceuticals Enters Into European Patent Settlement, Global License Agreement With Teva", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "alder biopharmaceuticals inc", "sentiment": "negative"}, {"name": "teva", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Alder Biopharmaceuticals Inc:\n* ALDER BIOPHARMACEUTICALS® ENTERS INTO EUROPEAN PATENT SETTLEMENT AND GLOBAL LICENSE AGREEMENT WITH TEVA IN THE FIELD OF ANTI-CGRP-BASED THERAPY\n* ALDER BIOPHARMACEUTICALS INC - ‍ALDER HAS AGREED TO MAKE AN IMMEDIATE ONE-TIME PAYMENT OF $25 MILLION TO TEVA​\n* ALDER BIOPHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT, ALDER HAS AGREED TO WITHDRAW ITS APPEAL BEFORE EUROPEAN PATENT OFFICE\n* ALDER BIOPHARMACEUTICALS - UNDER TERMS CO AGREED TO PAY $75 MILLION AT EACH OF TWO SALES-RELATED MILESTONES FOLLOWING COMMERCIAL LAUNCH OF EPTINEZUMAB\n* ALDER SAYS UNDER TERMS CO AGREED TO PROVIDE CERTAIN ROYALTY PAYMENTS ON NET SALES AT RATES FROM 5% TO 7% FOLLOWING COMMERCIAL LAUNCH OF EPTINEZUMAB\n* ALDER - UNDER TERMS CO AGREED TO MAKE SECOND ONE-TIME PAYMENT OF $25 MILLION UPON APPROVAL OF BLA FOR EPTINEZUMAB WITH U.S. FDA Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T21:33:00.000+02:00", "crawled": "2018-01-09T16:50:59.033+02:00", "highlightTitle": ""}